Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial

Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
402 participant HCQ prophylaxis RCT with results not reported over 3 years after completion. Authors note 283 patients completed the trial, but no results are available to date.
38 HCQ RCTs have results missing long after expected1-38
The trials report a total of 25,399 patients, with 12 trials having actual enrollment of 8,139, and the remainder estimated.
Niriella et al., 3 Jul 2020, Double Blind Randomized Controlled Trial, placebo-controlled, trial SLCTR/2020/011. Contact: madunil.niriella@kln.ac.lk (corresponding author).
This PaperHCQAll
Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial
Madunil A Niriella, Dileepa S Ediriweera, Arjuna P De Silva, Ranjan Premarathne, Priyantha Balasooriya, Kaluthanthri D Duminda, Neelika G Malavige, Kamani Wanigasuriya, Sarath Lekamwasam, Senanayake A Kularathne, Sisira Siribaddana, Hithanadura J De Silva, Saroj Jayasinghe
Trials, doi:10.1186/s13063-020-04659-7
Background: The first case of a coronavirus 2019 (COVID-19) infection in a Sri Lankan was reported on March 11, 2020. The situation in Sri Lanka changed with the rapid increase of personnel contracting COVID-19 in a naval base camp that housed more than 4000 people. This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread. Our aim is to study the effectiveness and safety of HCQ for PEP among naval personnel with exposure to COVID-19-positive patients. Methods/design: This is a placebo-controlled, randomized, clinical trial carried out in the naval base camp and quarantine centers of the Sri Lanka Navy, Ministry of Defense, Sri Lanka. Navy personnel who are exposed to a patient with confirmed COVID-19 infection but test negative for the virus on reverse real-time polymerase chain reaction (rRT-PCR) at recruitment will be randomized, 200 to each arm, to receive HCQ or placebo and monitored for the development of symptoms or rRT-PCR positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus for 14 days. Discussion: This trial will provide high-quality evidence of the effectiveness and safety of HCQ as PEP for COVID-19. The study design is unique due to the circumstances of the outbreak in a confined area among otherwise healthy adults, at a relatively early stage of its spread. Trial registration: Sri Lanka Clinical Trials Registry (SLCTR) SLCTR/2020/011. Registered on
Ethics approval and consent to participate Ethical clearance for the study was obtained from the Ethics Review Committee (ERC) of the Faculty of Medicine, University of Kelaniya, Ragama-P/22/04/2020. Written, informed consent to participate will be obtained from all participants. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Cevik, Bamford, Ho, COVID-19 pandemic -a focused review for clinicians, Clin Microbiol Infect
Das, Pareek, Mathur, Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, doubleblind, placebo controlled clinical trial--an Indian experience, Curr Med Res Opin, doi:10.1185/030079907X219634
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol, doi:10.1038/s41584-020-0372-x
Shelar, BMC to try out hydroxychloroquine as prophylaxis in Dharavi. Worli Koliwada: The Hindu
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Who, Laboratory testing for coronavirus disease (COVID-19) in suspected human cases
{ 'indexed': {'date-parts': [[2022, 12, 9]], 'date-time': '2022-12-09T05:17:46Z', 'timestamp': 1670563066584}, 'reference-count': 17, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2020, 8, 27]], 'date-time': '2020-08-27T00:00:00Z', 'timestamp': 1598486400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2020, 8, 27]], 'date-time': '2020-08-27T00:00:00Z', 'timestamp': 1598486400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>The first case of a coronavirus 2019 (COVID-19) infection in a Sri ' 'Lankan was reported on March 11, 2020. The situation in Sri Lanka changed with the rapid ' 'increase of personnel contracting COVID-19 in a naval base camp that housed more than 4000 ' 'people. This provided a unique opportunity to study the effectiveness of hydroxychloroquine ' '(HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public ' 'health measures to prevent spread. Our aim is to study the effectiveness and safety of HCQ ' 'for PEP among naval personnel with exposure to COVID-19-positive patients.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods/design</jats:title>\n' ' <jats:p>This is a placebo-controlled, randomized, clinical trial carried out ' 'in the naval base camp and quarantine centers of the Sri Lanka Navy, Ministry of Defense, Sri ' 'Lanka. Navy personnel who are exposed to a patient with confirmed COVID-19 infection but test ' 'negative for the virus on reverse real-time polymerase chain reaction (rRT-PCR) at ' 'recruitment will be randomized, 200 to each arm, to receive HCQ or placebo and monitored for ' 'the development of symptoms or rRT-PCR positivity for severe acute respiratory syndrome ' 'coronavirus 2 (SARS-CoV-2) virus for 14\u2009days.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Discussion</jats:title>\n' ' <jats:p>This trial will provide high-quality evidence of the effectiveness ' 'and safety of HCQ as PEP for COVID-19. The study design is unique due to the circumstances of ' 'the outbreak in a confined area among otherwise healthy adults, at a relatively early stage ' 'of its spread.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Trial registration</jats:title>\n' ' <jats:p>Sri Lanka Clinical Trials Registry (SLCTR) <jats:ext-link ' 'xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" ' 'xlink:href="https://slctr.lk/trials/slctr-2020-011">SLCTR/2020/011</jats:ext-link>. ' 'Registered on 04 May 2020</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s13063-020-04659-7', 'type': 'journal-article', 'created': {'date-parts': [[2020, 8, 27]], 'date-time': '2020-08-27T13:04:15Z', 'timestamp': 1598533455000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 3, 'title': 'Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: ' 'study protocol for a randomized, controlled trial', 'prefix': '10.1186', 'volume': '21', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7213-5858', 'authenticated-orcid': False, 'given': 'Madunil A.', 'family': 'Niriella', 'sequence': 'first', 'affiliation': []}, {'given': 'Dileepa S.', 'family': 'Ediriweera', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arjuna P.', 'family': 'De Silva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ranjan', 'family': 'Premarathne', 'sequence': 'additional', 'affiliation': []}, {'given': 'Priyantha', 'family': 'Balasooriya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kaluthanthri D.', 'family': 'Duminda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Neelika G.', 'family': 'Malavige', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kamani', 'family': 'Wanigasuriya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sarath', 'family': 'Lekamwasam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Senanayake A.', 'family': 'Kularathne', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sisira', 'family': 'Siribaddana', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hithanadura J.', 'family': 'de Silva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saroj', 'family': 'Jayasinghe', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 8, 27]]}, 'reference': [ { 'issue': '7', 'key': '4659_CR1', 'doi-asserted-by': 'publisher', 'first-page': '842', 'DOI': '10.1016/j.cmi.2020.04.023', 'volume': '26', 'author': 'M Cevik', 'year': '2020', 'unstructured': 'Cevik M, Bamford C, Ho A. COVID-19 pandemic – a focused review for ' 'clinicians. Clin Microbiol Infect. 2020;26(7):842–7.', 'journal-title': 'Clin Microbiol Infect'}, { 'key': '4659_CR2', 'doi-asserted-by': 'publisher', 'unstructured': 'Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown ' 'apparent efficacy in treatment of COVID-19 associated pneumonia in ' 'clinical studies. Biosci Trends. 2020;14(1):72–3. ' 'https://doi.org/10.5582/bst.2020.01047.', 'DOI': '10.5582/bst.2020.01047'}, { 'key': '4659_CR3', 'doi-asserted-by': 'publisher', 'unstructured': 'Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine ' 'and chloroquine: implications for rheumatology. Nat Rev Rheumatol. ' '2020;16(3):155–66. https://doi.org/10.1038/s41584-020-0372-x.', 'DOI': '10.1038/s41584-020-0372-x'}, { 'key': '4659_CR4', 'doi-asserted-by': 'publisher', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'volume': '6', 'author': 'J Liu', 'year': '2020', 'unstructured': 'Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative ' 'of chloroquine, is effective in inhibiting SARS-CoV-2 infection in ' 'vitro. Cell Discov. 2020;6:16. ' 'https://doi.org/10.1038/s41421-020-0156-0.', 'journal-title': 'Cell Discov'}, { 'key': '4659_CR5', 'doi-asserted-by': 'publisher', 'unstructured': 'Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively ' 'inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. ' 'Cell Res. 2020;30(3):269–71. https://doi.org/10.1038/s41422-020-0282-0.', 'DOI': '10.1038/s41422-020-0282-0'}, { 'issue': '9', 'key': '4659_CR6', 'doi-asserted-by': 'publisher', 'first-page': '2227', 'DOI': '10.1185/030079907X219634', 'volume': '23', 'author': 'SK Das', 'year': '2007', 'unstructured': 'Das SK, Pareek A, Mathur DS, et al. Efficacy and safety of ' 'hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, ' 'double-blind, placebo controlled clinical trial--an Indian experience. ' 'Curr Med Res Opin. 2007;23(9):2227–34. ' 'https://doi.org/10.1185/030079907X219634.', 'journal-title': 'Curr Med Res Opin'}, { 'key': '4659_CR7', 'unstructured': 'Hydroxychloroquine post exposure prophylaxis for coronavirus disease ' '(COVID-19). https://clinicaltrials.gov/ct2/show/NCT04318444. Accessed 31 ' 'July 2020.'}, { 'key': '4659_CR8', 'unstructured': 'Safety and Efficacy of Hydroxychloroquine for at Risk Population (SHARP) ' 'against COVID-19 (SHARP COVID-19). ' 'https://clinicaltrials.gov/ct2/show/NCT04342156. Accessed 31 July 2020.'}, { 'key': '4659_CR9', 'unstructured': 'Chloroquine/hydroxychloroquine prevention of coronavirus disease ' '(COVID-19) in the healthcare setting (COPCOV). ' 'https://clinicaltrials.gov/ct2/show/NCT04303507. Accessed 31 July 2020.'}, { 'key': '4659_CR10', 'unstructured': 'Post-exposure prophylaxis/preemptive therapy for SARS-Coronavirus-2 ' '(COVID-19 PEP). https://clinicaltrials.gov/ct2/show/NCT04308668. ' 'Accessed 31 July 2020.'}, { 'key': '4659_CR11', 'volume-title': 'Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 ' 'infection', 'author': 'National Taskforce for COVID-19', 'year': '2020', 'unstructured': 'National Taskforce for COVID-19. Advisory on the use of ' 'hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection. 2020. ' 'https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf. ' 'Accessed 7 May 2020.'}, { 'key': '4659_CR12', 'volume-title': 'BMC to try out hydroxychloroquine as prophylaxis in Dharavi', 'author': 'J Shelar', 'year': '2020', 'unstructured': 'Shelar J. BMC to try out hydroxychloroquine as prophylaxis in Dharavi. ' 'Worli Koliwada: The Hindu; 2020. ' 'https://www.thehindu.com/news/cities/mumbai/bmc-to-try-out-hydroxychloroquine-as-prophylaxis-in-dharavi-worli-koliwada/article31335133.ece. ' 'Accessed 7 May 2020.'}, { 'key': '4659_CR13', 'unstructured': 'Hydroxychloroquine post exposure prophylaxis for coronavirus disease ' '(COVID-19). https://clinicaltrials.gov/ct2/show/NCT04318444. Accessed 7 ' 'May 2020.'}, { 'key': '4659_CR14', 'unstructured': 'Safety and Efficacy of Hydroxychloroquine for at Risk Population (SHARP) ' 'against COVID-19 (SHARP COVID-19). ' 'https://clinicaltrials.gov/ct2/show/NCT04342156. Accessed 7 May 2020.'}, { 'key': '4659_CR15', 'unstructured': 'Chloroquine/hydroxychloroquine prevention of coronavirus disease ' '(COVID-19) in the healthcare setting (COPCOV). ' 'https://clinicaltrials.gov/ct2/show/NCT04303507. Accessed 7 May 2020.'}, { 'key': '4659_CR16', 'unstructured': 'Post-exposure prophylaxis/preemptive therapy for SARS-Coronavirus-2 ' '(COVID-19 PEP). https://clinicaltrials.gov/ct2/show/NCT04308668. ' 'Accessed 7 May 2020.'}, { 'key': '4659_CR17', 'unstructured': 'WHO. Laboratory testing for coronavirus disease (COVID-19) in suspected ' 'human cases. https://apps.who.int/iris/rest/bitstreams/1272454/retrieve. ' 'Accessed 7 May 2020.'}], 'container-title': 'Trials', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s13063-020-04659-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s13063-020-04659-7/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s13063-020-04659-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 8]], 'date-time': '2022-12-08T23:02:59Z', 'timestamp': 1670540579000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04659-7'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 8, 27]]}, 'references-count': 17, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2020, 12]]}}, 'alternative-id': ['4659'], 'URL': 'http://dx.doi.org/10.1186/s13063-020-04659-7', 'relation': {}, 'ISSN': ['1745-6215'], 'subject': ['Pharmacology (medical)', 'Medicine (miscellaneous)'], 'container-title-short': 'Trials', 'published': {'date-parts': [[2020, 8, 27]]}, 'assertion': [ { 'value': '18 May 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '6 August 2020', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '27 August 2020', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'Ethical clearance for the study was obtained from the Ethics Review Committee ' '(ERC) of the Faculty of Medicine, University of Kelaniya, Ragama—P/22/04/2020. ' 'Written, informed consent to participate will be obtained from all ' 'participants.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'Not applicable.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare that they have no competing interests.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '748'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit